USPTO serial 97575104
LION
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- WLODARCZYK, CAROLYN A
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with LION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*
Plus Government fees of $150
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seattle, WA, US
Seattle, WA, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Draeke H. Weseman
Draeke H. Weseman Greenberg Traurig, LLP90 South Seventh Street, Suite 3500Minneapolis, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Nanoparticle formulations as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents comprising cationic nanoparticle compositions that complex with one or more nucleic acids for the purpose of delivering such nucleic acid to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoemulsion compositions as components of nucleic acid-based vaccines, medicines, and pharmaceutical preparations, namely, nucleic acid drug delivery agents in the nature of compounds combining liquid oils, lipids, and surfactants to form nanoparticles to facilitate the delivery of nucleic acids to biological cells, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Therapeutic preparations in the nature of vaccines as drug delivery agents consisting of nucleic acid, protein or small-molecule compounds for medicines that facilitate the delivery of a wide range of pharmaceuticals delivered via intramuscular injections, intravenous injections, inhalation, transdermal, intradermal, or intranasal methods, for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations as components of immunotherapeutics, namely, pharmaceutical preparations in the nature of vaccines and nucleic acid, protein or small-molecule medicines for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredient drug delivery agents consisting of compositions in the nature of cationic nanoparticles that facilitate the delivery of medical, biological, pharmaceutical, and therapeutic preparations to biological cells for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Nanoparticles and nanoparticle formulations in the nature of compositions for use as drug delivery agents sold as an integral component of pharmaceutical preparations; Nanoparticles and nanoparticle formulations in the nature of active pharmaceutical ingredients for use as drug delivery agents consisting of a biological composition in the form of nanoparticles sold as an integral component of pharmaceutical preparations for intracellular delivery of nucleic acid to biological cells for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases, all for pharmaceutical or medical purposes; Pharmaceutical preparations, namely, lipid-enabled drug delivery systems for nucleic acid, protein or small-molecule medicines comprising small interfering RNA, messenger RNA, antisense, microRNA, DNA, cDNA oligotherapeutic, protein therapeutic agents, and small molecules that facilitate the delivery of pharmaceutical preparations to biological cells to enable the targeting of any gene in the human genome to modulate immune response, sold to pharmaceutical companies for use as an integral component for use in the further manufacture of pharmaceutical preparations for the treatment and prevention of a wide variety of diseases, namely, cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations for the treatment and prevention of cancers, infectious diseases, and of rare and orphan diseases in the nature of cancers and infectious diseases; Pharmaceutical preparations, namely, nucleic acid-based delivery agents comprised of nanoparticle carriers and polymers for the delivery of nucleic acid to human cells; Drug carriers for medical use, namely, drug delivery agents consisting of cationic nanoparticles as compositions that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents consisting of emulsions as compositions that facilitate delivery of a wide range of pharmaceuticals | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 14, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 14, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 10, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 10, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 5, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Mar 5, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Mar 4, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Mar 4, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 13, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 12, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Nov 12, 2025 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Sep 10, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Sep 10, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 11, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jan 14, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 14, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 20, 2024 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Dec 20, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 20, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 20, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 20, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 20, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 14, 2024 | DPCC | DIVISIONAL PROCESSING COMPLETE | — |
| Nov 12, 2024 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Nov 12, 2024 | ALIE | ASSIGNED TO LIE | — |
| Aug 28, 2024 | DRRR | DIVISIONAL REQUEST RECEIVED | — |
| Aug 28, 2024 | ERTD | TEAS REQUEST TO DIVIDE RECEIVED | — |
| Aug 28, 2024 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Aug 28, 2024 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Aug 28, 2024 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Aug 28, 2024 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Apr 26, 2024 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Apr 26, 2024 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Feb 28, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Feb 28, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Feb 28, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 15, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 13, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 13, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 12, 2023 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Oct 12, 2023 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jul 13, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 13, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 9, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 5, 2022 | NWAP | NEW APPLICATION ENTERED | — |